Tag
This review synthesizes evidence demonstrating that continuous glucose monitoring (CGM) metrics, particularly time above 140 mg/dL, predict progression to stage 3 type 1 diabetes with accuracy comparable to oral glucose tolerance test (OGTT
A landmark simulation study demonstrates that adding remote patient monitoring to continuous glucose monitoring in pediatric T1D patients significantly improves QALYs and is highly cost-effective compared to standard care.
A multi-trial analysis reveals that CGM-derived Time Below Range (TBR) lacks the predictive power to serve as a standalone biomarker for severe hypoglycemia, highlighting the need for multi-factorial risk assessment in Type 1 Diabetes.
A practical, clinician-friendly summary of the American Diabetes Association’s 2024 Standards of Care, highlighting new recommendations on GLP-1/GIP therapy, SGLT2 inhibitors, continuous glucose monitoring, and individualized care.
